These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies.
    Author: Donalson K, Turner S, Wastell H, Cuckle H.
    Journal: Prenat Diagn; 2008 Oct; 28(10):904-7. PubMed ID: 18785180.
    Abstract:
    OBJECTIVE: To estimate the utility of maternal serum ADAM12 as a Down's syndrome marker. METHODS: Samples from 71 Down's syndrome affected pregnancies were retrieved from - 20 degrees C storage together with 710 controls matched for gestation and storage time. ADAM12 was measured prior to identification of the affected pregnancies, and expressed in multiples of the gestation-specific median (MoM). RESULTS: The median ADAM12 level in the affected pregnancies was 1.36 MoM with a 10th-90th centile range of 0.90-1.94 MoM compared with 1.01 and 0.65-1.52 MoM in the unaffected control pregnancies (P = < 0.0001, two-side Wilcoxon Rank Sum Test). The Mahalanobis distance between the medians was 0.96 compared with 0.92, 1.18, 1.07 and 1.24 for alpha-fetoprotein, intact human chorionic gonadotrophin (hCG), unconjugated estriol and inhibin-A respectively in the same samples. In unaffected pregnancies there were highly statistically significant correlations between ADAM12 and each of the other markers; in the affected pregnancies the only significant correlations were with hCG (P< or =0.0001) and inhibin-A (P< or =0.05). Statistical modelling predicted that ADAM12 as a fifth marker could increase the detection rate by 2-3% or reduce the false-positive rate by 0.9-1.7%. CONCLUSIONS: ADAM12 is a second trimester marker of Down's syndrome, with discriminatory power similar to existing markers. It could be considered in multi-marker combinations.
    [Abstract] [Full Text] [Related] [New Search]